MannKind Investor Relations Material
Latest events
M&A Announcement
MannKind
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from MannKind Corporation
Access all reports
MannKind Corporation is a biopharmaceutical company focused on the development and commercialization of therapeutic products for patients with diabetes and pulmonary diseases. The company’s flagship product is an inhalable insulin used to manage blood sugar levels in adults with diabetes. MannKind is also exploring its proprietary Technosphere platform for the delivery of other therapeutic agents via inhalation, aiming to improve treatment options for various chronic conditions. The company is headquartered in Danbury, Connecticut, and its shares are listed on the NASDAQ.
Key slides for MannKind Corporation
Jefferies Global Healthcare Conference 2025
MannKind Corporation
Jefferies Global Healthcare Conference 2025
MannKind Corporation
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
MNKD
Country
🇺🇸 United States